Wire · opportunities
Twice-Daily Deuruxolitinib Outperformes Once-Daily in Severe AA
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 September 2026 · Fusion42 review
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib significantly outperformed once-daily dosing in treating severe alopecia areata, leading to its selection for pivotal phase 3 trials and subsequent FDA approval in 2024. Safety profiles were comparable between dosing schedules, with mostly mild to moderate adverse events.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You must prioritise twice-daily deuruxolitinib dosing in severe alopecia areata development to match FDA-approved standards and clinical efficacy benchmarks. Single daily dosing now risks being viewed as suboptimal and could limit clinical acceptance.
◆ Coverage
1 source · 23 Sep 2026
◆ Related on Wire
◆ Topics